xGen® Acute Myeloid Leukemia Cancer Panel v1.0
The xGen® Acute Myeloid Leukemia Cancer Panel is a target enrichment solution for next generation sequencing (NGS) composed of more than 11,500 xGen Lockdown® Probes targeting 260 genes implicated in acute myeloid leukemia (AML). This 1.2 Mb panel was developed as part of The Cancer Genome Atlas (TCGA) project collaboration . The capture probes are biotin-modified oligonucleotides individually synthesized using proprietary IDT Ultramer® synthesis technology, ensuring probes of the highest quality and industry-leading yields of full-length product. The AML Cancer Panel also offers an unprecedented level of flexibility, including allowing for expansion to cover more targets, and can also be used as a supplement for exome enrichment.
The xGen AML Cancer Panel is empirically derived from 200 patient samples and achieves coverage of >99.9% of target regions with highly uniform enrichment (Figure 1). The panel is compatible with the optimized xGen 4-hour Capture Protocol, which allows sequencing to be started on the same day that target capture is performed. This stocked, functionally validated product is shipped in 1 business day after an order is received.
Figure 1. Highly Uniform Enrichment from xGen® AML Cancer Panel. A 4-plex target capture of human genomic DNA (Coriell) performed using the xGen AML Cancer Panel using TruSeq® LT libraries was sequenced on an Illumina MiSeq using 2 x 150 paired-end reads. A cumulative 31.8M reads were generated for all 4 samples. Greater than 98% of targets are covered at >0.2 of the mean coverage. Mean coverage depth ranged from 218X to 510X as a result of expected sample-to-sample variability.
To order the xGen AML Cancer Panel, or for more information about this and other NGS products from IDT, go to www.idtdna.com/xgen.
- Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368(22):2059–2074.